In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Beiersdorf sales

This article was originally published in The Rose Sheet

Executive Summary

Cosmed division revenues increased 7.2% to $699.3 mil. (€1=$.89) in first quarter, Beiersdorf announces in 1financial presentation April 23. Sales for the division, which includes the Nivea, La Prairie and Juvena brands, dropped 5.5% to $190.4 mil. in the Americas region, but experienced double-digit growth in Europe, excluding Germany, and in Africa, Asia and Australia, company says. Consolidated Q1 sales were $1.06 bil., up 3.6% from the prior-year period, which included sales from company's advanced wound care business, divested in the first quarter 2001. Cosmed division sales for the year will increase 8%, earnings before interest and taxes will advance 12%, Beiersdorf predicts. Company also reported full-year results on target with preliminary figures released in February (2"The Rose Sheet" Feb. 25, 2002, p. 3)...

You may also be interested in...



Juvena Ulti-Max Face To Debut As Q10 Extension

Swiss skin care marketer Juvena will unveil Ulti-Max Face this spring as an anti-aging product that offers a trio of benefits, the firm said

Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease

The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.

Brinavess' US Review: EU Postmarket Data Unlikely To Save Troubled AFib Drug

Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug;  FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.

UsernamePublicRestriction

Register

RS010234

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel